{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:14:43Z","timestamp":1793128483350,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023MB080"],"award-info":[{"award-number":["ZR2023MB080"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bmc.2025.118487","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:38:26Z","timestamp":1763444306000},"page":"118487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Novel oxadiazole analogs as anticancer agents: Design, synthesis, in vitro and in vivo biological evaluation, and computer studies of sphingosine kinase inhibitors"],"prefix":"10.1016","volume":"133","author":[{"given":"Fuxun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengguo","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118487_bb0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12935-019-1014-8","article-title":"Roles of sphingosine-1-phosphate signaling in cancer","volume":"19","author":"Wang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.bmc.2025.118487_bb0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1042\/BST20110602","article-title":"Sphingosine 1-phosphate signalling in cancer","volume":"40","author":"Pyne","year":"2012","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bmc.2025.118487_bb0015","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1021\/jm4011687","article-title":"Importance of sphingosine kinase (SphK) as a target in developing Cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors","volume":"57","author":"Plano","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118487_bb0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11427-017-9046-6","article-title":"Targeting sphingosine-1-phosphate signaling for cancer therapy","volume":"60","author":"Xie","year":"2017","journal-title":"Sci China-Life Sci"},{"key":"10.1016\/j.bmc.2025.118487_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0378-1119(00)00205-5","article-title":"Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution","volume":"251","author":"Melendez","year":"2000","journal-title":"Gene"},{"key":"10.1016\/j.bmc.2025.118487_bb0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0090-6980(01)00111-3","article-title":"Sphingosine-1-phosphate phosphatases","volume":"64","author":"Mandala","year":"2001","journal-title":"Prostaglandins & Other Lipid Mediators"},{"key":"10.1016\/j.bmc.2025.118487_bb0035","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1074\/jbc.M209514200","article-title":"Identification and characterization of a novel human sphingosine-1-phosphate phosphohydrolase, hSPP2","volume":"278","author":"Ogawa","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118487_bb0040","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/imm.12272","article-title":"Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond","volume":"142","author":"Garris","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.bmc.2025.118487_bb0045","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.1176709","article-title":"Regulation of histone acetylation in the nucleus by Sphingosine-1-phosphate","volume":"325","author":"Hait","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bmc.2025.118487_bb0050","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1194\/jlr.R046300","article-title":"An update on the biology of sphingosine 1-phosphate receptors","volume":"55","author":"Blaho","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.bmc.2025.118487_bb0055","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1021\/acs.jmedchem.6b01575","article-title":"Modulators of Sphingosine-1-phosphate pathway biology: recent advances of Sphingosine-1-phosphate receptor 1 (S1P1) agonists and future perspectives","volume":"60","author":"Dyckman","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118487_bb0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling: lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmc.2025.118487_bb0065","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.bbamem.2006.08.009","article-title":"Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy","volume":"1758","author":"Zheng","year":"2006","journal-title":"Biochim Biophys Acta-Biomembr"},{"key":"10.1016\/j.bmc.2025.118487_bb0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature13475","article-title":"Sphingolipid metabolites in inflammatory disease","volume":"510","author":"Maceyka","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118487_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-7091-1511-4_1","article-title":"Sphingosine kinase\/sphingosine 1-phosphate Signaling in Cancer therapeutics and drug resistance","volume":"216","author":"Selvam","year":"2013","journal-title":"Sphingolipids Dis"},{"key":"10.1016\/j.bmc.2025.118487_bb0080","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1007\/s13277-015-4700-8","article-title":"Sphingosine kinase 2 promotes colorectal cancer cell proliferation and invasion by enhancing MYC expression","volume":"37","author":"Zhang","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.bmc.2025.118487_bb0085","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13046-015-0205-y","article-title":"Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo","volume":"34","author":"Xun","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118487_bb0090","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1096\/fj.10-167502","article-title":"Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration","volume":"25","author":"Strub","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.bmc.2025.118487_bb0095","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1016\/j.bmcl.2015.03.041","article-title":"Structure-activity relationship studies of the lipophilic tail region of sphingosine kinase 2 inhibitors","volume":"25","author":"Congdon","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118487_bb0100","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1021\/acs.jmedchem.9b00162","article-title":"Topographical mapping of isoform-selectivity determinants for J-channel-binding inhibitors of sphingosine kinases 1 and 2","volume":"62","author":"Adams","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118487_bb0105","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.str.2013.02.025","article-title":"Molecular basis of sphingosine kinase 1 substrate recognition and catalysis","volume":"21","author":"Wang","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.bmc.2025.118487_bb0110","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1021\/ml5004074","article-title":"Crystal structure of sphingosine kinase 1 with PF-543","volume":"5","author":"Wang","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118487_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114401","article-title":"Therapeutic potential of the sphingosine kinase 1 inhibitor, PF-543","volume":"163","author":"Yi","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2025.118487_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.141392","article-title":"Sphingosine kinase 2 in cancer: a review of its expression, function, and inhibitor development","volume":"306","author":"Luo","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.bmc.2025.118487_bb0125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/BJ20111929","article-title":"Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1","volume":"444","author":"Schnute","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.bmc.2025.118487_bb0130","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1021\/acs.jmedchem.7b00070","article-title":"Discovery of a potent and selective sphingosine kinase 1 inhibitor through the molecular combination of chemotype-distinct screening hits","volume":"60","author":"Schnute","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118487_bb0135","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/jm501760d","article-title":"Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1-and SphK2-selective inhibitors","volume":"58","author":"Patwardhan","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118487_bb0140","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1016\/j.bmcl.2013.06.030","article-title":"Structure guided design of a series of sphingosine kinase (SphK) inhibitors","volume":"23","author":"Gustin","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118487_bb0145","first-page":"5962","article-title":"Discovery and evaluation of inhibitors of human sphingosine kinase","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2025.118487_bb0150","article-title":"Biological characterization of 3-(2-amino-ethyl)-5- 3-(4-butoxyl-phenyl)-propylidene -thiazolidine-2,4-dione (K145) as a selective sphingosine Kinase-2 inhibitor and anticancer agent","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2025.118487_bb0155","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s10620-007-0133-6","article-title":"Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase","volume":"53","author":"Maines","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bmc.2025.118487_bb0160","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1021\/acs.jmedchem.9b01508","article-title":"Discovery of a small side cavity in sphingosine kinase 2 that enhances inhibitor potency and selectivity","volume":"63","author":"Sibley","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118487_bb0165","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-16-2363","article-title":"A phase I study of ABC294640, a first-in-class sphingosine Kinase-2 inhibitor, in patients with advanced solid tumors","volume":"23","author":"Britten","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2025.118487_bb0170","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1021\/acs.jcim.8b00931","article-title":"In silico characterization of structural distinctions between isoforms of human and mouse sphingosine kinases for accelerating drug discovery","volume":"59","author":"Worrell","year":"2019","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2025.118487_bb0175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cell.2016.12.026","article-title":"Nuclear localization of mitochondrial TCA cycle enzymes as a critical step in mammalian zygotic genome activation","volume":"168","author":"Nagaraj","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118487_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103369","article-title":"Synthesis and biological evaluation of 2-epi-jaspine B analogs as selective sphingosine kinase 1 inhibitors","volume":"98","author":"Yang","year":"2020","journal-title":"Bioorg Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:40:38Z","timestamp":1781253638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625004286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"alternative-id":["S0968089625004286"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118487","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel oxadiazole analogs as anticancer agents: Design, synthesis, in vitro and in vivo biological evaluation, and computer studies of sphingosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"118487"}}